MLV & Co.

In a note dated June 26, MLV & Co. analyst Paul Morgan initiated coverage on the Healthcare REIT Sector with a neutral view due to the balance of "attractive investment opportunities" and risks from a "rising interest rate environment." Within the sector, Morgan says...

In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on Sorrento Therapeutics (NASDAQ: SRNE) with a Buy rating and $9.00 price target. In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead...

In a report published Thursday, MLV & Co. analyst Vernon T. Bernardino downgraded the rating on ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) from Buy to Hold, and lowered the price target from $6.00 to $1.25. In the report, MLV & Co. noted, “We move from a BUY recommendation to HOLD and...

In a report published Wednesday, MLV & Co. analyst George B. Zavoico downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) from Buy to Hold, but raised the price target from $18.00 to $20.00. In the report, MLV & Co. noted, “2Q:13 was a transformational quarter for Acadia. On April 11, the...

In a report published Monday, MLV & Co. analyst Ryan Meliker upgraded American Campus Communities (NYSE: ACC) from Hold to Buy, and raised the price target from $48.00 to $50.00. In the report, MLV & Co. noted, “We are raising our rating on ACC to BUY from HOLD, driven by the fact that...

In a report published Friday, MLV analyst George B. Zavoico initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and $4.50 price target. In the report, MLV noted, “We are initiating coverage of Pluristem Therapeutics based on accumulating, though early, evidence of...

In a report published Wednesday, MLV analyst Jonathan Petersen downgraded the rating on CapLease (NYSE: LSE) from Buy to Hold, but raised the price target to $8.50. In the report, MLV noted, “This morning, CapLease (LSE) and American Realty Capital Properties (ARCP) announced that ARCP has...

In a report published Wednesday, MLV & Co. analyst downgraded the rating on Aastrom Biosciences (NASDAQ: ASTM) from Buy to Hold, and lowered the price target from $5.50 to $1.50. In the report, “At the forefront of investors minds has been Aastrom's enrollment progress in their Phase III trial...

In a report published Monday, MLV & Co. downgraded its rating on Dynavax Technologies Corporation (NASDAQ: DVAX) from Buy to Hold. MLV noted, “After months of DVAX stock volatility and speculation as to what the immediate future of Dynavax's lead product candidate, HEPLISAV, would be, the FDA...

In a report published Monday, MLV & Co. initiated coverage on Winthrop Realty Trust (NYSE: FUR) with a Buy rating and $13.50 price target. MLV noted, “We are initiating coverage of Winthrop Realty Trust (FUR) with a BUY rating and $13.50 price target. We believe FUR is uniquely positioned to...